Beam Therapeutics Inc. Proceeds from Debt, Net of Issuance Costs
Beam Therapeutics Inc. (BEAM) reported Proceeds from Debt, Net of Issuance Costs of $93.89 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromDebtNetOfIssuanceCosts · last filed 2026-08-04
- Beam Therapeutics Inc. proceeds from debt, net of issuance costs for the quarter ending 2026-06-30 was $0.00.
- Beam Therapeutics Inc. proceeds from debt, net of issuance costs for the quarter ending 2026-03-31 was $93.89M.
- Beam Therapeutics Inc. proceeds from debt, net of issuance costs for the quarter ending 2025-06-30 was $0.00.
- Beam Therapeutics Inc. proceeds from debt, net of issuance costs for the quarter ending 2025-03-31 was $0.00.
| Period end | Proceeds from Debt, Net of Issuance Costs 3 month | Proceeds from Debt, Net of Issuance Costs 6 month |
|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $93.89M 10-Q · filed 2026-08-04 |
| 2026-03-31 | $93.89M 10-Q · filed 2026-05-07 | |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $0.00 10-Q · filed 2026-08-04 |
| 2025-03-31 | $0.00 10-Q · filed 2026-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |